Volume 6.01 | Jan 16

Mammary Cell News 6.01 January 16, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
Clonal Analysis via Barcoding Reveals Diverse Growth and Differentiation of Transplanted Mouse and Human Mammary Stem Cells
Researchers described a lentiviral genomic-barcoding and analysis strategy and its use to compare the clonal outputs of transplants of purified mouse and human basal mammary epithelial cells. They found that both sources of transplanted cells produced many bilineage mammary epithelial clones in primary recipients, although primary clones containing only one detectable mammary lineage were also common. [Cell Stem Cell] Abstract | Graphical Abstract
Culture and Characterize Mouse Mammary Epithelial Progenitors with Serum-Free EpiCult-B (Mouse) - Free Protocols
PUBLICATIONS (Ranked by impact factor of the journal)

Differential Regulation of Estrogen Receptor a Expression in Breast Cancer Cells by Metastasis-Associated Protein 1
Researchers showed that silencing of metastasis-associated protein 1 (MTA1) reduced the level of expression of estrogen receptor (ER)a in ERa-positive cells but increased it in ERa-negative cells. In both MCF7 and MDA-MB-231, MTA1 was recruited to the region +146 to +461 bp downstream of the transcription start site of ESR1. [Cancer Res] Abstract

Angiopoietin-2 Mediates Blood-Brain Barrier Impairment and Colonization of Triple-Negative Breast Cancer Cells in Brain
Using in vivo mouse models for breast cancer metastasis in brain, researchers observed that triple-negative breast cancer cells crossed the blood-brain barrier, lodged in the brain microvasculature and remained adjacent to brain microvascular endothelial cells. [J Pathol] Abstract

Estrogen-Dependent Sushi Domain Containing 3 Regulates Cytoskeleton Organization and Migration in Breast Cancer Cells
Sushi domain containing 3 (SUSD3) is a significantly differentially expressed gene, with 3.38-fold higher mRNA levels in aromatase inhibitors-responsive breast tumors vs non-responders. SUSD3 was highly expressed in estrogen receptor-alpha (ERa)-positive breast tumors and treatment with estradiol increased SUSD3 expression in ERa-positive breast cancer cells. [Oncogene] Abstract

Toxicity of Nano Molybdenum Trioxide toward Invasive Breast Cancer Cells
Scientists investigated the cytotoxicity of molybdenum trioxide nanoplates towards invasive breast cancer iMCF-7 cells by analyzing morphological changes and performing Western blot and flow cytometry analyses. [ACS Appl Mater Interfaces] Abstract

The Anthelmintic Drug Niclosamide Induces Apoptosis, Impairs Metastasis and Reduces Immunosuppressive Cells in Breast Cancer Model
The potency of niclosamide on breast cancer was assessed in vitro and in vivo. Researchers found that niclosamide showed a dramatic growth inhibition against breast cancer cell lines and induced apoptosis of 4T1 cells in a dose-dependent manner. [PLoS One] Full Article

INPP4B Overexpression Enhances the Antitumor Efficacy of PARP Inhibitor AG014699 in MDA-MB-231 Triple-Negative Breast Cancer Cells
Researchers used a triple-negative breast cancer cell line MDA-MB-231 without expression of inositol polyphosphate 4-phosphatase type II (INPP4B) as the study model and a lentiviral system to stably overexpress INPP4B gene in MDA-MB-231 cells. They detected that the overexpression of INPP4B could significantly suppress cell proliferation and block cell cycle progression in G1 phase via decreasing the protein level of phosphorylated AKT. [Tumor Biol] Abstract

BMP9 Inhibits the Bone Metastasis of Breast Cancer Cells by Downregulating CCN2 (Connective Tissue Growth Factor, CTGF) Expression
Scientists showed that bone morphogenetic protein (BMP)9 inhibit the bone metastasis of breast cancer cells by activating the BMP/Smad signaling pathway and downregulating CTGF; however, when CTGF expression was maintained, the inhibitory effect of BMP9 on the MDA-MB-231 cells was abolished. [Mol Biol Rep] Abstract

Involvement of Polypyrimidine Tract-Binding Protein (PTBP1) in Maintaining Breast Cancer Cell Growth and Malignant Properties
Knockdown of PTBP1 expression substantially inhibited tumor cell growth, colony formation in soft agar and in vitro invasiveness of breast cancer cell lines, a result similar to what has been reported in ovarian cancer. [Oncogenesis] Full Article


Phase III Trial of Nonpegylated Liposomal Doxorubicin in Combination with Trastuzumab and Paclitaxel in HER2-Positive Metastatic Breast Cancer
Investigators conducted a randomized Phase III trial of first-line nonpegylated liposomal doxorubicin plus trastuzumab and paclitaxel versus trastuzumab plus paclitaxel in patients with human epidermal growth factor 2 receptor (HER2)-positive metastatic breast cancer. [Ann Oncol] Abstract

Induction of Wnt-Inducible Signaling Protein-1 Correlates with Invasive Breast Cancer Oncogenesis and Reduced Type 1 Cell-Mediated Cytotoxic Immunity: A Retrospective Study
Scientists found that type 1 cell-mediated cytotoxic immunity was correlated with increased survival in patients with invasive breast cancer, especially in patients with invasive triple negative breast cancer. Oncogenic transformation in invasive breast cancer was associated with an increase in Wnt-inducible signaling protein-1. [PLoS Comput Biol]
Full Article

Use Aldefluor to Detect Breast Cancer Stem Cells - Click here to learn more - 645x110
Stress Signaling and the Shaping of the Mammary Tissue in Development and Cancer
The authors review recent advances made in the field of stress signaling pathways and its roles in mammary gland organogenesis, how they contribute to normal organ specification and homeostasis and how its subversion by oncogenes leads to cancer. [Oncogene] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Generex Announces Completion of Enrollment of Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
Generex Biotechnology Corporation announced completion of enrollment of the Antigen Express, Inc. AE37 breast cancer immunotherapy trial. The clinical trial is designed to assess the ability of AE37 to reduce the risk of relapse in patients who have had breast cancer. [Generex Biotechnology Corporation] Press Release

Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase III Clinical Study in Patients with Metastatic Breast Cancer
Nektar Therapeutics announced that the Independent Data Monitoring Committee (DMC) created to provide safety oversight for the Company’s pivotal clinical study for etirinotecan pegol has recommended continuation of the BEACON Phase III trial, based upon the completion of a planned interim efficacy analysis in accordance with the DMC charter. [Nektar Therapeutics] Press Release

AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) for Patients with Early-Stage Triple-Negative Breast Cancer
AbbVie announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib when added to carboplatin, a chemotherapy, in women with early-stage, triple-negative breast cancer. [AbbVie] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Maximizing the Value of Imaging in Oncology Drug Development
March 12-13, 2014
London, United Kingdom

NEW The Future of Experimental Medicine Conference 2014
March 16-19, 2014
Sydney, Australia

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Fellow – Morphogenetic Signaling Pathways in Development and Disease (University of Rochester Medical Center)

NEW 2 Postdoctoral Positions – Spatial Single Cell Systems Biology of Breast Cancer (University of Zurich)

NEW PhD Scholarship – Chromosome Instability in Breast Cancer (The University of Queensland)

Postdoctoral Research Fellow (Brigham & Women’s Hospital and Harvard Medical School)

PhD Position – Grading CIN in the Mammary Gland (European Molecular Biology Laboratory)

Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Postdoctoral Position – Breast Cancer Signaling (Weizmann Institute of Science)

Postdoctoral Associate – Breast Cancer Development (University of Pittsburgh Cancer Institute)

Clinical MD – Clinical Development Program for Oncology and Autoimmune Diseases (Immunomedics, Inc.)

Chief Medical Officer – Novel Therapeutics in Oncology and Autoimmune Disease (Immunomedics, Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Mammary Cell News: Archives | Events | Contact Us